We are a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth.
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
ROIC dropped from -31.71% to -34.00%, capital efficiency is deteriorating. Negative free cash flow of -$49M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$68M
▼ -34.7% YoY
Op. Margin
—
ROIC
-33.19%
▼ -2.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$53M
▼ -9.5% YoY
Op. Cash Flow (TTM)
-$53M
▼ -9.6% YoY
Net Debt
-$185M
Net Cash Position
Cash & Equiv.
$195M
Continue Research